PuSH - Publication Server of Helmholtz Zentrum München

Huppmann, M.* ; Baumgarten, A.* ; Ziegler, A.-G.* ; Bonifacio, E.*

Neonatal Bacille Camette-Guerin vaccination and type 1 diabetes.

Diabetes Care 28, 1204-1206 (2005)
DOI PMC
Open Access Green as soon as Postprint is submitted to ZB.
Type I diabetes is a genetic disorder that is associated with the early development of automimunity against islet beta-cells (1). The a priori genetically determined risk for type I diabetes is modified by mostly unknown environmental factors that are thought to contribute to the increasing incidences of childhood diabetes in the last decade. Changes in exposure to environment are also discussed as a potential means to reduce the incidence of type I diabetes. Adjuvant therapy that includes vaccinations with agents such as Bacille Calmette-Guerin (BCG), for example, have been proposed as beneficial modifiers of the immune system that can reduce the incidence of autoimmune diabetes in animal models (2). In humans, there have also been sporadic reports of preserving beta-cell function when BCG vaccination is administered soon after diabetes onset (3), and it has been suggested that BCG vaccination early in childhood could reduce the incidence of type 1. diabetes. Hence, there is substantial interest in whether immunostimulation with BCG could be used as a primary, secondary, or tertiary vaccination strategy for type I diabetes.
Altmetric
Additional Metrics?
[➜Log in]
Edit extra informations Login
Publication type Article: Journal article
Document type Scientific Article
ISSN (print) / ISBN 0149-5992
e-ISSN 1935-5548
Journal Diabetes Care
Quellenangaben Volume: 28, Issue: 5, Pages: 1204-1206 Article Number: , Supplement: ,
Publisher American Diabetes Association
Publishing Place Alexandria, Va.
Reviewing status Peer reviewed
Institute(s) Institute of Diabetes and Obesity (IDO)
Institute of Diabetes Research (IDF)
Institute of Pancreatic Islet Research (IPI)